| 词条 | Anifrolumab |
| 释义 |
| type = mab | image = | alt = | mab_type = mab | source = u | target = Interferon α/β receptor | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | ChemSpiderID = none | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Intravenous | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1326232-46-5 | KEGG = D11082 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | C=6444 | H=9964 | N=1712 | O=2018 | S=44 | molecular_weight = 145.12 kg/mol }} Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus (SLE).[2] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. The drug was developed by MedImmune, a unit of AstraZeneca, which chose to move anifrolumab instead of sifalimumab into phase III trials for lupus in 2015.[3][4][5] Clinical trial resultsAnifrolumab failed to meet its endpoint of significant reduction in disease as assessed by the SLE Responder Index 4 instrument in the TULIP 1 phase III trial[6]. This multi-center, double-blind, placebo-controlled study followed adults with moderate to severe SLE over the course of one year. Preliminary results were announced on 31 August 2018. Adverse effectsThe most common adverse effect was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.[7] References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109 | journal = WHO Drug Information | volume = 27 | issue = 2 | year = 2013 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL109.pdf | format=PDF}} {{Monoclonals for immune system}}{{Cytokine receptor modulators}}{{monoclonal-antibody-stub}}2. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Anifrolumab, American Medical Association. 3. ^{{cite web|title=Press release: New Hope for Lupus Patients|url=https://www.medimmune.com/about-us/media/new-hope-for-lupus-patients-20150811.html|publisher=MedImmune|archiveurl=https://web.archive.org/web/20170731052844/https://www.medimmune.com/about-us/media/new-hope-for-lupus-patients-20150811.html|archivedate=31 July 2017|language=en|date=11 August 2015}} 4. ^{{cite web|title=Anifrolumab|url=https://www.sps.nhs.uk/medicines/anifrolumab/|publisher=NHS Specialist Pharmacy Service|accessdate=31 July 2017}} 5. ^{{cite web|title=Anifrolumab|url=http://adisinsight.springer.com/drugs/800021494|publisher=AdisInsight|accessdate=31 July 2017|language=en}} 6. ^{{Cite web|url=https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html|title=Update on TULIP 1 Phase III trial for anifrolumab in systemic lupus erythematosus|website=www.astrazeneca.com|language=en|access-date=2019-02-05}} 7. ^{{cite journal | author = H. Spreitzer | date = 29 August 2016 | title = Neue Wirkstoffe - Anifrolumab | journal = Österreichische Apothekerzeitung | issue = 18/2016 | language = German }} 3 : Cutaneous lupus erythematosus|Monoclonal antibodies|Experimental drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。